Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
Status:
Recruiting
Trial end date:
2025-02-14
Target enrollment:
Participant gender:
Summary
This is a multicenter non-inferiority study, designed to establish non-inferiority of the
study treatment rituximab compared with the comparator ocrelizumab for consecutively included
patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60
years.
Phase:
Phase 3
Details
Lead Sponsor:
Haukeland University Hospital
Collaborators:
Helse Stavanger HF Oslo University Hospital St. Olavs Hospital University Hospital of North Norway University Hospital, Akershus